Journal of Psychiatry and Neuroscience articles from November 2004

Journal of Psychiatry and Neuroscience archives from November 2004

Nitric oxide: a key player in the relation between cardiovascular disease and major depressive disorder?(Editorial)
November 1, 2004... There is now a substantial body of evidence suggesting a strong relation between cardiovascular disease (CVD) and major depressive disorder (MDD). MDD has been shown to be an independent predictor of poorer cardiovascular outcome not only after...

The role of the hippocampus in the pathophysiology of major depression.(Review Paper/Examen critique)
November 1, 2004... Converging lines of research suggest that the hippocampal complex (HC) may have a role in the pathophysiology of major depressive disorder (MDD). Although postmortem studies show little cellular death in the HC of depressed patients, animal...

Interactions between [beta]-amyloid and central cholinergic neurons: implications for Alzheimer's disease.(Review Paper/Examen critique)
November 1, 2004... Alzheimer's disease is an age-related neurodegenerative disorder that is characterized by a progressive loss of memory and deterioration of higher cognitive functions. The brain of an individual with Alzheimer's disease exhibits extracellular...

Testing the association between thyroid dysfunction and psychiatric diagnostic group in an iodine-deficient area.(Research Paper/Article de recherche)
November 1, 2004... Objective: To test the association between thyroid dysfunction and psychiatric diagnostic group in a large sample of consecutive patients, while controlling for the effects of age, sex, medication and concomitant medical conditions. Methods: We...

Potential benefits of quetiapine in the treatment of substance dependence disorders.(Research Paper/Article de recherche)
November 1, 2004... Objective: Some antipsychotic medications prescribed for the treatment of psychoses, mood disorders or post-traumatic stress disorder in patients with coexisting substance dependence disorders (SDD) have reduced substance dependence. We studied...

Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission.(Research Paper/Article de recherche)
November 1, 2004... Objective: Corticotropin-releasing factor (CRF), the major adrenocorticotropic hormone (ACTH) secretagogue, acts within the brain to integrate the stress responses of the central nervous, endocrine and immune systems. The involvement of this...

Tardive dyskinesia in 2 patients treated with ziprasidone.(Brief Report/Rapport sommaire)
November 1, 2004... Ziprasidone is an atypical antipsychotic drug that is believed to have a low propensity for inducing extrapyramidal symptoms, including tardive dyskinesia (TD). Two of our patients developed TD after 23 months and 34 months of ziprasidone...

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology: Kingston, Ontario, Canada, May 29 to June 1, 2004.(CCNP News and Views/Nouvelles et opinions du CCNP)
November 1, 2004... Some highlights of the 27th Annual Meeting of the Canadian College of Neuropsychopharmacology (CCNP) are briefly described here. A full report is available online. Plenary lectures The first plenary lecture, given by Dr. A.G. Phillips,...

Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs?(Psychopharmacology for the Clinician/Psychopharmacologie pratique)
November 1, 2004... The acute phase of depression is often accompanied by anxiety, irritability, insomnia and anxiety disorders. As a result, the concomitant use of an anxiolytic agent with an antidepressant is often necessary. Selective serotonin reuptake...